N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway
Inventors
Bhamra, Inder • Bingham, Matilda • Testar, Richard • Sargent, Louise • Donoghue, Craig
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
Core Innovation
The invention concerns pharmaceutical formulations comprising a compound of formula (III) and a pharmaceutically acceptable excipient, with X1 and X2 selected from CR6 and N, provided that one of X1 and X2 is CR6 and the other is N. The compound includes two 6-membered N-containing heteroaryl rings, het2 and het3, which may be unsubstituted or substituted with groups selected from halo, C1-4 alkyl, C1-4 haloalkyl, ORA1, NRA1RB1, CN, and NRA1C(O)RB1.
The structure further constrains R1 and R2 to be each H. R3 is selected from H, C1-4 alkyl, C1-4 haloalkyl, and C3-6 cycloalkyl, while R4 is independently selected at each occurrence from halo, C1-4 alkyl, C1-4 haloalkyl, CN, ORA4, NRA4RB4, SO2RA4, C3-6 cycloalkyl, and C3-6 halocycloalkyl. R5 and R6 are independently selected at each occurrence from H, halo, C1-4 alkyl, C1-4 haloalkyl, ORA2, NRA2RB2, CN, SO2RA2, and C3-6 cycloalkyl.
The parameters m and n restrict the framework, with m set to 1 and n selected from 0, 1 or 2. The disclosed compounds include tightly defined substituted amide-linked heteroaryl/heterocycle derivatives within a pharmaceutical formulation, and the partial disclosure also describes monoarylated acetamide compounds featuring N-rich heteroaryl rings such as pyridine, pyrimidine, pyrazine, and pyrazole.
Claims Coverage
The consolidated claim coverage includes one independent claim. It centers on a pharmaceutical formulation comprising a compound of formula (III) with seven inventive features: the CR6/N arrangement at X1/X2, two 6-membered N-containing heteroaryl rings, fixed R1 and R2 as H, constrained substituent sets for R3 to R6, ring parameters m and n, allowed selections for RA1/RB1/RA2/RB2/RA4/RB4, and a pharmaceutically acceptable excipient.
Pharmaceutical formulation with compound of formula (III)
A pharmaceutical formulation comprising a compound of formula (III) together with a pharmaceutically acceptable excipient.
X1/X2 constraint with CR6 and N
X1 and X2 are selected from CR6 and N, provided that one of X1 and X2 is CR6 and the other is N.
Het2 6-membered N-containing heteroaryl ring substitution
Het2 is a 6 membered heteroaryl ring containing 1, 2 or 3 N heteroatoms which may be unsubstituted or substituted with 1, 2 or 3 groups independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, ORA1, NRA1RB1, CN, and NRA1C(O)RB1.
Het3 6-membered N-containing heteroaryl ring substitution
Het3 is a 6 membered heteroaryl ring containing 1, 2 or 3 N heteroatoms which may be unsubstituted or substituted with 1, 2 or 3 groups independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, ORA1, NRA1RB1, CN, and NRA1C(O)RB1.
Fixed R1 and R2 as H
R1 and R2 are each H.
R3, R4, R5, and R6 substituent ranges and independence
R3 is selected from H, C1-4 alkyl, C1-4 haloalkyl, and C3-6 cycloalkyl; R4 is independently selected at each occurrence from halo, C1-4 alkyl, C1-4 haloalkyl, CN, ORA4, NRA4RB4, SO2RA4, C3-6 cycloalkyl and C3-6 halocycloalkyl; R5 and R6 are independently selected at each occurrence from H, halo, C1-4 alkyl, C1-4 haloalkyl, ORA2, NRA2RB2, CN, SO2RA2, and C3-6 cycloalkyl.
Ring parameter constraints m and n
m is 1 and n is selected from 0, 1 or 2.
Allowed selections for substituent groups RA1/RB1/RA2/RB2/RA4/RB4
RA1, RB1, RA2, RB2, RA4 and RB4 are at each occurrence independently selected from H, C1-4 alkyl, and C1-4 haloalkyl.
The independent claim covers a pharmaceutical formulation containing a compound of formula (III) defined by the CR6/N relationship for X1/X2, two substituted 6-membered N-containing heteroaryl rings, fixed R1/R2 as H, constrained choices for R3 to R6, and m=1 with n selected from 0, 1 or 2, together with a pharmaceutically acceptable excipient.
Stated Advantages
Improved solubility.
Reduced cytotoxicity.
Suitable pharmacokinetics.
Documented Applications
Dual-Cell beta-Catenin Wnt reporter assay evaluation using Wnt-3a/L-Wnt cells and Leading Light Wnt Reporter Cells, with a luciferase assay (One-glo) and IC50 values categorized as +, ++, and +++ for many compounds.
Treating Wnt/Porcupine-mediated cancers.
Treating Wnt/Porcupine-mediated conditions.
Specificity immunoprecipitation evaluation.
Cell death evaluation.
Foci formation evaluation.
Interested in licensing this patent?